HMGA1 and myxoid liposarcoma: While the NF-κB pathway has already been described as being associated with trabectedin resistance in myxoid liposarcoma [26], we decided to explore the inhibition of the mTOR pathway in combination with trabectedin, since to our knowledge, specific HMGA1 inhibitors are not currently available for research.